224 related articles for article (PubMed ID: 35662390)
1. Central role for p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy.
Ono M; Komatsu M; Ji B; Takado Y; Shimojo M; Minamihisamatsu T; Warabi E; Yanagawa T; Matsumoto G; Aoki I; Kanaan NM; Suhara T; Sahara N; Higuchi M
Aging Cell; 2022 Jul; 21(7):e13615. PubMed ID: 35662390
[TBL] [Abstract][Full Text] [Related]
2. The cargo receptor SQSTM1 ameliorates neurofibrillary tangle pathology and spreading through selective targeting of pathological MAPT (microtubule associated protein tau).
Xu Y; Zhang S; Zheng H
Autophagy; 2019 Apr; 15(4):583-598. PubMed ID: 30290707
[TBL] [Abstract][Full Text] [Related]
3. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy.
Iba M; Guo JL; McBride JD; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2013 Jan; 33(3):1024-37. PubMed ID: 23325240
[TBL] [Abstract][Full Text] [Related]
4. P62 accumulates through neuroanatomical circuits in response to tauopathy propagation.
Blaudin de Thé FX; Lassus B; Schaler AW; Fowler SL; Goulbourne CN; Jeggo R; Mannoury la Cour C; Millan MJ; Duff KE
Acta Neuropathol Commun; 2021 Nov; 9(1):177. PubMed ID: 34727983
[TBL] [Abstract][Full Text] [Related]
5. Dendritic Spine Remodeling and Synaptic Tau Levels in PS19 Tauopathy Mice.
Walker CK; Greathouse KM; Boros BD; Poovey EH; Clearman KR; Ramdas R; Muhammad HM; Herskowitz JH
Neuroscience; 2021 Feb; 455():195-211. PubMed ID: 33346120
[TBL] [Abstract][Full Text] [Related]
6. Targeting tauopathy with engineered tau-degrading intrabodies.
Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM
Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765
[TBL] [Abstract][Full Text] [Related]
7. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy.
Ou W; Yang J; Simanauskaite J; Choi M; Castellanos DM; Chang R; Sun J; Jagadeesan N; Parfitt KD; Cribbs DH; Sumbria RK
J Neuroinflammation; 2021 Dec; 18(1):312. PubMed ID: 34972522
[TBL] [Abstract][Full Text] [Related]
8. Decrease of neuronal FKBP4/FKBP52 modulates perinuclear lysosomal positioning and MAPT/Tau behavior during MAPT/Tau-induced proteotoxic stress.
Chambraud B; Daguinot C; Guillemeau K; Genet M; Dounane O; Meduri G; Poüs C; Baulieu EE; Giustiniani J
Autophagy; 2021 Nov; 17(11):3491-3510. PubMed ID: 33459145
[TBL] [Abstract][Full Text] [Related]
9. Behavioural Functions and Cerebral Blood Flow in a P301S Tauopathy Mouse Model: A Time-Course Study.
Ahmad F; Mein H; Jing Y; Zhang H; Liu P
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575885
[TBL] [Abstract][Full Text] [Related]
10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
11. Tau oligomers as potential targets for early diagnosis of tauopathy.
Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
[TBL] [Abstract][Full Text] [Related]
12. Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model.
Ponnusamy M; Wang S; Yuksel M; Hansen MT; Blazier DM; McMillan JD; Zhang X; Dammer EB; Collier L; Thinakaran G
Brain; 2023 Apr; 146(4):1561-1579. PubMed ID: 36059072
[TBL] [Abstract][Full Text] [Related]
13. [Neurodegeneration and inflammation: analysis of a FTDP-17 model mouse].
Yoshiyama Y
Rinsho Shinkeigaku; 2008 Nov; 48(11):910-2. PubMed ID: 19198115
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice.
Liu M; Wang L; Gao J; Dong Q; Perry G; Ma X; Wang X
J Alzheimers Dis; 2019; 69(4):1077-1087. PubMed ID: 31156179
[TBL] [Abstract][Full Text] [Related]
15. Deposition of Phosphorylated α-Synuclein and Activation of GSK-3β and PP2A in the PS19 Mouse Model of Tauopathy.
Takaichi Y; Chambers JK; Ano Y; Takashima A; Nakayama H; Uchida K
J Neuropathol Exp Neurol; 2021 Sep; 80(8):731-740. PubMed ID: 34151989
[TBL] [Abstract][Full Text] [Related]
16. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice.
Yukawa K; Yamamoto-Mcguire S; Cafaro L; Hong C; Kamme F; Ikezu T; Ikezu S
Acta Neuropathol Commun; 2023 Oct; 11(1):166. PubMed ID: 37853497
[TBL] [Abstract][Full Text] [Related]
18. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections.
Iba M; McBride JD; Guo JL; Zhang B; Trojanowski JQ; Lee VM
Acta Neuropathol; 2015 Sep; 130(3):349-62. PubMed ID: 26150341
[TBL] [Abstract][Full Text] [Related]
19. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy.
Choi YB; Dunn-Meynell AA; Marchese M; Blumberg BM; Gaindh D; Dowling PC; Lu W
Alzheimers Res Ther; 2021 Jan; 13(1):32. PubMed ID: 33504364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
